Crinetics Pharmaceuticals Target Price

Analysts' average 12-month price target for Crinetics Pharmaceuticals is $82.

Get informed when a big investor buys or sells

+ Follow

Share Price

$84.95

Average Target Price

$81.70

3.8% downside

10 analysts in the last 4 months

High: $88 | Low: $55

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-07-28	UBS	$85	0.1% upside
2026-07-08	Stifel NicolausAlex Thompson	$85	0.1% upside
2026-07-08	Evercore ISI	$85	0.1% upside
2026-07-07	Jefferies	$85	0.1% upside
2026-07-07	H.C. Wainwright	$85	0.1% upside
2026-07-07	Robert W. Baird	$85	0.1% upside
2026-07-02	UBSAshwani Verma	$55	35.3% downside
2026-06-22	Stifel NicolausAlex Thompson	$83	2.3% downside
2026-06-15	H.C. WainwrightDouglas Tsao	$81	4.6% downside
2026-05-15	Evercore ISIGavin Clark-Gartner	$88	3.6% upside
2026-05-11	Oppenheimer	$84	1.1% downside
2026-01-30	Stifel Nicolaus	$84	1.1% downside
2026-01-12	Goldman SachsRichard Law	$67	21.1% downside
2026-01-08	Morgan Stanley	$87	2.4% upside
2026-01-08	China Renaissance Securities (US) Inc.	$105	23.6% upside
2026-01-05	Evercore ISI	$90	5.9% upside
2026-01-05	Stifel NicolausAlex Thompson	$75	11.7% downside
2025-09-30	Oppenheimer	$87	2.4% upside
2025-09-28	Morgan Stanley	$77	9.4% downside
2025-09-26	JMP SecuritiesJonathan Wolleben	$143	68.3% upside
2025-07-10	Goldman SachsRichard Law	$36	57.6% downside
2025-03-24	Stifel NicolausAlex Thompson	$60	29.4% downside
2025-02-28	JMP Securities	$91	7.1% upside
2024-08-09	H.C. WainwrightDouglas Tsao	$69	18.8% downside
2024-06-04	OppenheimerLeland Gershell	$74	12.9% downside
2024-05-23	Robert W. BairdBrian Skorney	$62	27% downside
2024-05-22	Morgan StanleyJeffrey Hung	$70	17.6% downside
2024-05-07	Piper SandlerYasmeen Rahimi	$97	14.2% upside
2024-03-20	JMP SecuritiesJonathan Wolleben	$80	5.8% downside
2024-03-13	OppenheimerLeland Gershell	$54	36.4% downside
2023-08-31	OppenheimerLeland Gershell	$40	52.9% downside
2022-05-26	Leerink Partners	$39	54.1% downside

Crinetics Pharmaceuticals (CRNX) FAQ

Crinetics Pharmaceuticals (CRNX) currently reports a target price of $82. Use the charts on this page to explore Crinetics Pharmaceuticals's target price history and peer comparisons.

Analysts' average 12-month price target for Crinetics Pharmaceuticals is $82, about 3.8% downside from the current share price of $84.95. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $82, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Crinetics Pharmaceuticals, and consider following CRNX for alerts when major investors trade the stock.

Crinetics Pharmaceuticals is classified in the Healthcare sector. On target price, it currently shows $82. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CRNX with unrelated industries.